Enhanced Lithium-Induced Brain Recovery Following Cranial Irradiation Is Not Impeded by Inflammation

JORDANE MALATERRE,a CAMERON S. MCPHERSON,a,b DELPHINE DENOYER,a EMILY LAI,b JIM HAGEKYRIAKOU,a SALLY LIGHTOWLER,a KOISHI SHUDO,c MATTHIAS ERNST,d DAVID M. ASHLEY,e JENNIFER L. SHORT,b GREG WHEELER,a ROBERT G. RAMSAYa,f,g

ABSTRACT

Radiation-induced brain injury occurs in many patients receiving cranial radiation therapy, and these deleterious effects are most profound in younger patients. Impaired neurocognitive functions in both humans and rodents are associated with inflammation, demyelination, and neural stem cell dysfunction. Here we evaluated the utility of lithium and a synthetic retinoid receptor agonist in reducing damage in a model of brain-focused irradiation in juvenile mice. We found that lithium stimulated brain progenitor cell proliferation and differentiation following cranial irradiation while also preventing oligodendrocyte loss in the dentate gyrus of juvenile mice. In response to inflammation induced by radiation, which may have encumbered the optimal reparative action of lithium, we used the anti-inflammatory synthetic retinoid Am80 that is in clinical use in the treatment of acute promyelocytic leukemia. Although Am80 reduced the number of cyclooxygenase-2-positive microglial cells following radiation treatment, it did not enhance lithium-induced neurogenesis recovery, and this alone was not significantly different from the effect of lithium on this proinflammatory response. Similarly, lithium was superior to Am80 in supporting the restoration of new doublecortin-positive neurons following irradiation. These data suggest that lithium is superior in its restorative effects to blocking inflammation alone, at least in the case of Am80. Because lithium has been in routine clinical practice for 60 years, these preclinical studies indicate that this drug might be beneficial in reducing post-therapy late effects in patients receiving cranial radiotherapy and that blocking inflammation in this context may not be as advantageous as previously suggested.

INTRODUCTION

Cranial irradiation is used in the treatment of primary and metastatic central nervous system tumors and prophylactically to prevent cranial relapse in high-risk acute lymphoblastic leukemia and lung cancer. In many instances subacute effects including behavioral changes, sleepiness, and late delayed cognitive effects manifested as lowered intelligence quotients and reduced learning and memory performances are experienced following these treatments [1]. The severity of these side effects is increased with higher doses, larger brain volumes, and a younger age at treatment [2, 3]. A range of cellular alterations have been proposed to be responsible for these debilitating side effects identified in rodents, primates, and humans, such as neural stem and progenitor cell (NSPC) loss, demyelination, and brain inflammation.

NSPCs play a critical role in the renewal of adult brain cells in germinative areas involved in learning and memory: the dentate gyrus (DG) in the hippocampus and the subventricular zone (SVZ)/olfactory bulb system [4–6]. Indeed, loss of NSPCs is associated with impairment of cognitive function following irradiation in both rodents and humans [7, 8]. As a strategy to minimize the effects of irradiation on brain cells, we considered interventions that might promote neurogenesis and repair after radiation injury. Lithium has been in clinical use for 60 years and remains a treatment of choice for bipolar disorder [9]. Experimental evidence supports the idea that lithium can be used efficiently in the treatment of radiation-induced brain damage [10, 11]. In contrast to a previous study [11], we used lithium as a postradiotherapy treatment to prevent sensitizing endogenous NSPCs to radiation. However, the efficiency of lithium treatment within this context may have potentially been limited by inflammation induced following irradiation [7, 12]. We therefore investigated whether...
the concomitant use of lithium and inflammatory suppression might achieve an optimal neural cell recovery following cranial irradiation. We focused on the use of a clinically used drug that could be dually applied both to achieve an anticancer therapeutic effect and to reduce inflammation. One such candidate molecules is the synthetic retinoid Am80 (tambinobetone), because it is a promising drug in regard to cancer treatment and has been used already to reduce brain inflammation. Indeed Am80 is clinically approved for relapsed or refractory acute promyelocytic leukemia (APL) and has the advantage over all-trans-retinoic acid to be more stable and to drive the differentiation of APL cells [13]. Importantly, Am80 has been recently shown to reduce brain inflammation following hemorrhage and to promote behavioral recovery [14]. We found here that Am80 can be used to efficiently reduce irradiation-induced microglial cell activation, which mediates inflammation, but that this provided no additional benefit beyond the lithium-alone-induced recovery of neurogenesis.

**Materials and Methods**

**Animal and Experimental Treatment**

Juvenile C57Bl/6 male 3–5-week-old mice were used in this study. All of the experiments were conducted according to the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. For cranial irradiation, the mice were placed after anesthesia on polypropylene plastic beds and irradiated using the 9 MeV electron beam from a Varian linear accelerator delivering a single dose of 8 Gy. To achieve this, the mouse bodies excluding their heads were protected by a precisely machined Perspex (E-Plas, Tullamarine, VIC, Australia, http://www.eplas.com.au) sheet and a 3-mm lead shield. In rodents, a single dose of 8 Gy produces long-term NSPC proliferation and neurogenesis impairment [15] and is equivalent to a fractionated dose of 20 Gy in 2-Gy doses. The calculation was done as follows: effective dose (2 Gy per fraction) = total dose (α/β + fraction size)/(α/β + 2), so in this instance the effective dose = 8(2 + 8)/(2 + 2) = 20. The α/β ratio describes the tissue tolerance, and an α/β value of 2 is used for brain tissue [16]. For lithium treatment (LiCO3; Sigma-Aldrich, St. Louis, http://www.sigmaaldrich.com), the mice were fed with control chow or containing 0.1% Triton X-100) for 10 minutes at room temperature (RT). The sections were incubated with mouse anti-BrdU antibody (1/100; DakoCytomation) overnight at 4°C, and counterstained in Mayer’s hematoxylin, dehydrated, and coverslipped in Depex medium. For 2-N HCl treatment (RT). The sections were incubated in mouse anti-CNP antibody (1/500; Abcam, Cambridge, UK, http://www.abcam.com) at RT for 1 hour, rinsed in PBS, and incubated in ImmPress reagent (Vector Laboratories, Burlingame, CA, http://www.vectorlabs.com) for 30 minutes at RT. Staining for BrdU was visualized using diaminobenzidine and H2O2. The sections were then counterstained in Mayer’s hematoxylin, dehydrated, and coverslipped in Depex medium. For 2’,3’-cyclic nucleotide-3’-phosphohydrolase (CNP) and cyclooxygenase-2 (COX-2) staining, the HCl incubation step was omitted, and sections were incubated in mouse anti-CNP antibody (1/500; Abcam, Cambridge, UK, http://www.abcam.com) at RT for 1 hour or in rabbit anti-COX-2 antibody (1/300; Santa Cruz Biotechnology Inc., Santa Cruz, CA, http://www.scbt.com) overnight at 4°C after pressure cooker antigen retrieval in EDTA (1 mM) buffer. For immunofluorescence staining for BrdU and neuron-specific enolase (NSE) or glial fibrillary acidic protein (GFAP), following pressure cooker antigen retrieval in citrate buffer (10 mM) followed by 2 N HCl treatment for BrdU, the sections were incubated overnight at 4°C in appropriate secondary antibody mixture: mouse anti-BrdU antibody (1/100; DakoCytomation) and rabbit anti-NSE antibody (1/100; Chemicon, Temecula, CA, http://www.invitrogen.com) according to manufacturer’s instructions. Digestion of genomic DNA was performed by the addition of RNase-free DNase 1 (1 unit per μl; Promega, Madison, WI, http://www.promega.com). Superscript III Reverse Transcriptase (Invitrogen) was used for first-strand cDNA synthesis according to the manufacturer’s instructions. Quantitative reverse transcription-polymerase chain reactions (qRT-PCRs) were conducted using an ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, http://www.appliedbiosystems.com). For one reaction, 8 μl of cDNA (1:10 dilution) was combined with 10 μl of SyBr Green PCR Master Mix (Applied Biosystems) and 200 nM sense and antisense oligonucleotides (Gennworks, Hindmarsh, SA, Australia, http://www.gennworks.com.au) and amplified using temperatures of 50°C for 2 minutes and 95°C for 15 minutes. These initial steps were followed by 45 cycles of 95°C for 15 seconds and 60°C for 1 minute. Expression of all genes was normalized to β2-microglobulin (reverse, GTCCTGGCTCGGCCC, and forward, TTCACCCCACTGAGACT; TNFα: reverse, ACAAGCGAAGATGGAAGAGG, and forward, CTTGGACTGGCCAGAGAG; Cyclin D1: reverse, GTGCGTTTGGGCGGATAGAC, and forward, GCATCTACTGCAACACTCTAC; c-myc, reverse, CTCGGCACACCGGCTCCT, and forward, GCTGTAATTCCAGCGAGAGACA; interleukin-6 (IL6): reverse, GAAGTAGGGAGGGCGGTGG, and forward, CTGCAAGACTGACCATCAGTT; and IL6-Ra: reverse, GCAAACCGTGAACCTTTTG, and forward, GACCTGGGACCCGAGTTACTA).

**Immunohistochemistry**

The mice were deeply anesthetized, and brain tissues were fixed via transcardiac perfusion with 4% paraformaldehyde. The brains were processed for paraffin embedding and sectioning. For BrdU labeling and detection, after dewaxing and rehydration, 6-μm brain sections were subjected to 2 N HCl treatment for 30 minutes at 37°C. Endogenous peroxidase activities were quenched with 3% H2O2 in PBST (phosphate-buffered saline containing 0.1% Triton X-100) for 10 minutes at room temperature (RT). The sections were incubated with mouse anti-BrdU antibody (1/400; DakoCytomation, Glostrup, Denmark, http://www.dakocytomation.com) at RT for 1 hour, rinsed in PBS, and incubated in ImmPress reagent (Vector Laboratories, Burlingame, CA, http://www.vectorlabs.com) for 30 minutes at RT. Staining for BrdU was visualized using diaminobenzidine and H2O2. The sections were then counterstained in Mayer’s hematoxylin, dehydrated, and coverslipped in Depex medium. For 2’,3’-cyclic nucleotide-3’-phosphohydrolase (CNP) and cyclooxygenase-2 (COX-2) staining, the HCl incubation step was omitted, and sections were incubated in mouse anti-CNP antibody (1/500; Abcam, Cambridge, UK, http://www.abcam.com) at RT for 1 hour or in rabbit anti-COX-2 antibody (1/300; Santa Cruz Biotechnology Inc., Santa Cruz, CA, http://www.scbt.com) overnight at 4°C after pressure cooker antigen retrieval in EDTA (1 mM) buffer. For immunofluorescence staining for BrdU and neuron-specific enolase (NSE) or glial fibrillary acidic protein (GFAP), following pressure cooker antigen retrieval in citrate buffer (10 mM) followed by 2 N HCl treatment for BrdU, the sections were incubated overnight at 4°C in appropriate secondary antibody mixture: mouse anti-BrdU antibody (1/100; DakoCytomation) and rabbit anti-NSE antibody (1/100; Chemicon, Temecula, CA, http://www.invitrogen.com).
http://www.chemicon.com) or rabbit anti-GFAP antibodies (1/200; DakoCytomation) for adjacent sections. All of the sections were then washed, and secondary detection was performed using Alexa Fluor 594 goat anti-mouse IgG (for BrdU or CNP) or Alexa Fluor 488 goat anti-rabbit IgG (for GFAP or NSE). The sections were then mounted in a fluorescent mounting medium (DakoCytomation).

### Cell Quantitation and Statistical Analysis

Positive stained cells were scored in one-in-five series of three coded sections sampled from three areas throughout the rostral extent of the DG under high power magnification. DG areas were quantified using SPOT software (SPOT Imaging Solutions, Diagnostic Instruments, Inc., Sterling Heights, MI, http://www.spotimaging.com). The volume of DG was determined according to Shi and collaborators [18] by multiplying areas by the thickness of the sections. Cell densities were calculated by dividing cell numbers by the volume. Double-stained cells were analyzed on 0.3-μm optical sections using confocal microscopy.

### Behavioral Experiments

Behavioral studies were performed on two separate cohorts of mice, the first of which included 10 control and 10 irradiated mice, at 4 weeks after irradiation; the second cohort included 8 control and 7 irradiated mice, at 8 weeks after radiation. Investigators carrying out the experiments were blinded to the treatment of the mice. The open field is an open arena (40 cm × 40 cm × 30 cm) with a clear floor and walls and no distinguishing features. No visual cues were placed within or around the arena. The apparatus was placed on a table under a ceiling-mounted camera. Over three sequential days, the mice were singly placed in the center of the arena and left to explore for 30 minutes, thus determining habituation to the locomotor environment. The Spontaneous Motor Activity Recording & Tracking (SMART) video tracking system (San Diego Instruments, Inc., San Diego, http://www.sandiegoinstruments.com) was used to track the locomotor activity and analyze the total distance traveled (cm) in 5-minute time bins, as well as session totals. The Morris water maze consisted of a circular pool with a submerged platform 1 cm below the water surface [19]. The water was made opaque with nontoxic white paint and kept at 23 ± 2°C. The pool was divided into four equal quadrants (based on compass locations: north, south, east, and west). The experimental room contained various three-dimensional cues (door, computer, desk, curtain, flower, a stuffed toy, and a red striped placard, which served as external visual cues). Internal two-dimensional cues were placed at the north, south, east, and west cardinal points. Subject movements were recorded with a video camera positioned above the pool and attached to the ceiling. The data were analyzed using the SMART Video Tracking System. The program was used to measure the latency to locate the submerged platform, time spent in the target quadrant, platform crossings, time spent in the platform area, and platform proximity on probe trial days. Days 1 and 2 were the cue-associated learning phase (control procedure), in which the mice were trained for 2 days in two daily sessions; each session consisted of four 1-minute trials. The mice were randomly placed in different start positions and allowed 60 seconds to locate the platform indicated by a flag (12 cm visible above the water surface). The platform location was varied with each trial. The mice were left on the platform for 15 seconds after successful navigation; if a mouse failed to locate the platform after 60 seconds, it was led to the platform by a trailing finger. Days 3–5 were the spatial learning phase (acquisition phase), which was undertaken after the cue-associated learning phase. Spatial learning was completed over 3 days with mice undergoing eight trials per day in two sessions: each session consisted of four 1-minute trials. The mice were placed in different start positions and given 60 seconds to locate the submerged platform. The submerged platform location was randomized for each mouse; the location of the platform was kept constant for individual mice across subsequent spatial learning trials. After successful navigation to the platform, the mice were left for 15 seconds or manually placed on the platform if they were unable to locate the platform after 60 seconds. On day 6, a probe trial was conducted to check spatial reference memory. The platform was removed, and the mice were allowed to explore for 60 seconds. They were individually placed in the position furthest from (diametrically opposed to) the previous location of the submerged platform. For days 7–10, a reversal learning phase was performed 1 day after the spatial probe trial had been completed. The location of the submerged platform was moved to the diametrically opposed quadrant of the pool for each mouse. The same procedure was then followed as described for the spatial learning phase.

### Statistical Analysis

The data presented are the means ± SEM from at least three different mice. One-way analysis of variance with the Bonferroni post test or the Newman-Keuls post test was performed using GraphPad Prism version 5.00 for Windows (GraphPad Software, Inc., San Diego, http://www.graphpad.com).

### RESULTS

#### NSPC Proliferation Is Dampered in the DG Following Brain-Focused Irradiation and Is Associated with Subtle Cognitive Impairment in Juvenile Mouse

To ensure that the radiation treatment regimen we were testing produced a demonstrable effect on the proliferation of NSPCs in the DG of juvenile mouse, control and irradiated groups were injected with the thymidine analog BrdU 9 days following 8-Gy cranial ionizing radiation exposure. Immunohistochemical detection of cells that have incorporated BrdU into their DNA while progressing through the S phase at the time of the injection showed that irradiation led to a significant reduction in the number of proliferating cells in the DG (Fig. 1A, 1B) of irradiated mice compared with untreated control mice. To investigate whether irradiation in our model also produces a loss in oligodendrocytes, we quantified the number of CNP-positive (CNP⁺) oligodendrocytes as shown in Figure 1C. Scoring of CNP⁺ cell bodies showed that irradiation induced a significant reduction in the number of CNP⁺ oligodendrocytes in the DG of irradiated mice compared with control (Fig. 1D).

We then evaluated whether these cellular alterations were correlated with learning and memory abilities changes in juvenile mice in our paradigm at 4 and 8 weeks after irradiation (Fig. 2). This allowed the assessment of both subacute and delayed (late) cognitive impairments as seen in whole brain irradiation treated patients. To establish measures of these abilities we used the Morris water maze (MWM) as used by others to assess spatial learning related to hippocampal function. An open field
paradigm was used prior to challenging mice in MWM to assess locomotor and exploratory activity over 3 successive days. A robust habituation to the context was observed throughout the period of habituation, such that mice from all treatment groups were significantly less active by day 3 of habituation (Fig. 2A, 2B). Additionally, during each of the 3 days, control or irradiated mice demonstrated similar patterns of locomotor activity.

Hippocampus-related learning and memory function were then tested in the MWM. Spatial learning was assessed by training mice to locate a submerged platform. The mice were placed in different start positions and given 60 seconds to locate the submerged platform. The submerged platform location was randomized for each mouse. The location of the platform was kept constant for individual mice across subsequent spatial learning trials. After successful navigation to the platform, the mice were left for 15 seconds or manually placed on the platform if they were unable to locate the platform after 60 seconds. During five training sessions, irradiated and control mice alike demonstrated similar patterns of locomotor activity.

Here a significant difference in latency between control and irradiated mice was identified. Indeed irradiated mice tended to have a decreased latency after the first session. In groups assessed 4 weeks after irradiation, a difference was seen at session 5 (Fig. 2E). More consistent latency differences were identified between groups assessed 8 weeks after irradiation (Fig. 2F). Altogether our results suggest that a single dose of 8 Gy produces a subtle difference in learning and memory ability as assessed using MWM.

Lithium Promotes Neurogenesis and Prevents Oligodendrocytes Loss Following Cranial Irradiation in the DG In Vivo

The effect of lithium treatment on NSPC proliferation in the DG with or without cranial irradiation was then investigated. Accordingly mice were fed control or lithium chow for 1 week and received a 1-hour pulse of BrdU to assess the number of proliferating cells in the subgranular layer of the DG where NSPCs reside. This protocol achieved lithium levels in serum of 0.9 ± 0.01 mM in mice within the range of therapeutic concentrations used in humans (0.5–1.2 mM). Immunohistochemistry (IHC) detection of BrdU– cells suggested that lithium treatment increased the proportion of cells engaged in...
the S phase in the DG following irradiation (Fig. 1A). Quantitation of the number of these cells showed that lithium significantly reversed the effect of irradiation on NSPC proliferation in the DG of irradiated mice (Fig. 1B). These results indicate that DG NSPCs can be stimulated by lithium treatment following cranial irradiation.

To investigate whether the increase in NSPC proliferation translated into an increased number of newly generated cells, mice were injected with BrdU twice daily for 3 days 1 week following irradiation, and the number of BrdU− newborn cells was quantified 3 weeks later (4 weeks after radiation). Using this protocol, proliferating cells are no longer detectable because of BrdU dilution as a result of successive rounds of proliferation. As shown in Figure 3A, BrdU− cells were typically seen in the granular layer, in the hilus, and occasionally in the molecular layer of the DG. BrdU+/− cell quantitation (Fig. 3B) showed that irradiation produced a 50% decrease in the number of newborn cells after 3 weeks, whereas lithium induced a significant recovery in their number. These data support the view that lithium treatment enhances NSPC proliferation and neural cell birth.

Next, we investigated whether lithium enhances the differentiation of newly generated cells into neurons in vivo. The mice were injected with BrdU twice daily for 3 days 1 week following irradiation, and the fate of BrdU+/− cells was determined using coimmunostaining for BrdU and specific markers for neurons (NSE) or astrocyte marker GFAP (Fig. 4A). Using immunofluorescence and confocal microscopy, we found that lithium enhanced differentiation toward the neuronal lineage in lithium-treated mice compared with control mice following cranial irradiation as shown by BrdU and NSE costaining (Fig. 4A, 4B). In contrast, lithium treatment did not significantly affect glial differentiation as shown by BrdU and GFAP co-labeling (Fig. 4C).

To address the effects of irradiation and lithium treatment on demyelination, we quantified the number of differentiated oligodendrocytes identified by CNP IHC. Interestingly, we found that lithium restored the number of CNP+/− oligodendrocytes...
Neurosphere growth was assessed using \([3H]\)thymidine incorporation in the presence or absence of 0.5 or 1 mM lithium. This exposure is followed by 3 weeks, whereas lithium induced significant recovery in their irradiation-produced 50% decrease in the number of newborn cells. The data shown are the means ± SEM. Scale bar = 100 μm. *p < 0.05. Abbreviations: IR, irradiation; BrdU, 5-bromo-2′-deoxyuridine.

Following irradiation (Fig. 1C, 1D). These results suggest that lithium treatment stimulates NSPC proliferation and neuronal differentiation and reduces the loss of oligodendrocytes following cranial irradiation.

**Lithium Treatment Increases Cyclin D1 Expression in the DG Following Irradiation**

To investigate the molecular mechanism by which lithium stimulates NSPC proliferation, we evaluated the action of lithium on another population of NSPCs. In this instance NSPCs were isolated from the SVZ [20]. Indeed, in contrast to DG NSPCs, NSPCs derived from the SVZ can be efficiently expanded using the neurosphere assays (supplemental online Fig. 1A). NSPCs were plated at a density of \(10^5\) cells per milliliter into 96-well plates in the presence or absence of 0.5 or 1 mM lithium. This exposure is within the therapeutic range for humans (0.5–1.2 mM lithium). Neurosphere growth was assessed using \([3H]\)thymidine incorporation for 24 hours. Under both nonirradiated and irradiated conditions, 0.5 and 1 mM lithium increased neurosphere growth (supplemental online Fig. 1B). Quantitation confirmed a doubling in incorporated radioactivity in lithium-treated cultures compared with untreated cultures under both nonirradiated and irradiated conditions (supplemental online Fig. 1C). To rule out the possibility that \([3H]\)thymidine incorporation was occurring as a consequence of the repair process, we have also quantified neurosphere growth by viability assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (supplemental online Fig. 1D). We found that, in accord with the \([3H]\)thymidine incorporation experiment, adding 0.5 or 1 mM lithium increased neurosphere growth under both nonirradiated and irradiated conditions. Altogether these data suggest that lithium stimulates neurosphere cell proliferation.

Because lithium as been shown to activate the β-catenin-mediated signaling pathway, we measured the expression of one of its key target genes, Cyclin D1, at the mRNA level using qRT-PCR (supplemental online Fig. 1E). Neurospheres were incubated in 1 mM lithium for 24 hours after radiation to allow changes in transcription. Under these conditions we found that Cyclin D1 (supplemental online Fig. 1E) was upregulated by lithium treatment after radiation in NSPCs derived from SVZ. We then investigated whether our findings in SVZ derived NSPCs translated to DG NSPCs in vivo. The levels of Cyclin D1 and c-Myc mRNA, another β-catenin target gene, were measured in the hippocampus following 1 week of lithium treatment after irradiation using qRT-PCR (Fig. 5). Our results show that lithium treatment for 1 week following irradiation did not induce any significant change in either Cyclin D1 (Fig. 5A) or c-Myc mRNA expression level (Fig. 5B). However, IHC for Cyclin D1 presented in Figure 5C and 5D shows that Cyclin D1\(^+\) cells are more abundant in lithium-treated neurogenic regions compared with untreated after brain irradiation. This is likely to be a more sensitive measure of β-catenin target gene expression in the DG.

**Reduced Inflammation Is Not Required to Allow Increased Neurogenesis Following Brain-Focused Irradiation in Juvenile Mice In Vivo**

Irradiation-induced inflammation and subsequent gliosis is considered to functionally impair neurogenesis following irradiation [12]. We thus postulated that the suppression of inflammation might improve the stimulatory effect of lithium on neurogenesis following whole-brain irradiation in juvenile mice. With the aim of maximizing recovery, we introduced a combinatorial approach using lithium plus the synthetic retinoid Am80 (tamibarnetene) [13, 14, 21] to reduce inflammation. In these experiments, the mice were fed with Am80 chow (10 mg/kg) as previously described [17].

Initially we investigated the effect of Am80 on brain inflammation following irradiation by measuring the mRNA level of proinflammatory molecules. Therefore IL6, IL6-Rα, and TNFα mRNA expression were measured in the hippocampus of juvenile mice by qRT-PCR 1 and 4 weeks following irradiation. Interestingly we found that only TNFα mRNA (supplemental online Fig. 2A, 2B) but not IL6 mRNA (supplemental online Fig. 2C, 2D) or IL6-Rα mRNA (supplemental online Fig. 2E, 2F) expression was elevated in irradiated mice compared with unirradiated control mice only after 1 week. However, Am80 treatment over 4 weeks did not significantly reduce TNFα mRNA expression following irradiation.
Although we endeavored to isolate the hippocampal neurogenic regions for mRNA analysis, we suspected that the cells responsible for the production of these proinflammatory mediators are in the minority of the cell total. Accordingly we were concerned that any effects of Am80 might be overwhelmed by the presence of the total tissue content. Therefore to directly visualize the effect of irradiation and drug treatment on microglial activation, IHC for COX-2 was used (Fig. 6A, 6B). Indeed activated microglial cells are known to be the source of TNFα following irradiation [22, 23] and to robustly express the inflammatory molecule COX-2. Using this strategy to evaluate inflammation, we were able to demonstrate that the number of microglial cells expressing COX-2 after irradiation is significantly increased in the DG, and when mice are treated with Am80 for 4 weeks, this irradiation-induced increase is efficiently blocked. When lithium or lithium plus Am80 was administrated, the number of COX-2+ cells in the irradiated tissue was not different from the unirradiated control group. We then asked whether the two drug interventions had an effect on neurogenesis.

To specifically quantify the number of new neurons, we used the immature neuronal marker doublecortin (DCX), which has been shown to reflect the level of neurogenesis [24]. Quantitation of DCX+ cells demonstrated that lithium significantly increased the number of immature neurons following brain-focused irradiation (Fig. 7A, 7B). By contrast Am80 treatment alone did not increase the number of DCX-stained neuroblasts. Furthermore we found that when we used lithium and Am80 in combination, they were no more efficient in increasing the number of neuroblasts than lithium alone. This was an important experiment in establishing that inflammation was not alone in impeding neurogenesis or that it perturbs the positive action of lithium.

**DISCUSSION**

Our data demonstrate that lithium treatment promotes NSPC proliferation and neuronal differentiation and reduces oligodendrocyte loss in the DG of juvenile mice in a model of brain-focused irradiation in vivo. This model reproduces the deleterious effect of radiotherapy as seen in humans including NSPC loss, inflammation, and demyelination. These alterations are proposed to underpin the occurrence of subacute and delayed cognitive side effects observed in patients who are receiving whole brain irradiation during the course of cancer treatment. We also investigated the use of the synthetic retinoid Am80 with the prospect of achieving an optimal recovery in combination with lithium treatment.

NSPCs are extremely radiosensitive cells, and irradiation has been shown to produce long-lasting impairments in neurogenesis in vivo [25]. In rodents, lithium has been shown to exert a protective effect against ischemia [26–28] and neurodegeneration in mouse models of Alzheimer [29] and Huntington [30, 31]
diseases. In parallel, lithium positively influences neurogenesis in the DG [32, 33], and lithium pretreatment prior to irradiation improves cognitive performance of mice [11]. Our findings suggest that lithium reverses radiation-induced NSPC dysfunction by promoting neuronal progenitor proliferation and differentiation. These data are in line with studies showing that lithium increases neuronal differentiation [34, 35]. To take advantage of the stimulatory effect of lithium on neurogenesis following whole-brain irradiation, we tested whether we could enhance its action by blocking inflammation. To this end we combined lithium with a clinically used drug with the underlying idea that we could achieve both anticancer therapeutic effect and amelioration of radiotherapy side effects. With this in mind, we have focused our attention on the synthetic retinoid Am80 (tamibarotene), which is a potent drug clinically approved for relapsed or refractory APL and which has been recently shown to reduce brain inflammation following hemorrhage and to promote behavioral recovery [14]. Our results indicate that Am80 can be used to achieve

Figure 5. Effect of lithium treatment on Cyclin D1 and c-Myc expression following irradiation in vitro and in vivo. (A, B): Cyclin D1 (A) and c-Myc (B) mRNA expression was measured in the hippocampus by quantitative reverse transcription-polymerase chain reaction 1 week following brain-focused irradiation. (C): Immunohistochemistry (IHC) detection of Cyclin D1 was performed on brain sections obtained from control, irradiated, and lithium-treated mice. Photographs taken from stained coronal sections show that Cyclin D1⁺ cells were more abundant in lithium-treated samples compared with untreated samples following irradiation. Scale bars = 100 μm. (D): Quantitation of IHC for Cyclin D1. Lithium treatment restored the number of Cyclin D1⁺ cells to control levels following irradiation. Am80 treatment did not change the number of Cyclin D1⁺ cells. The data shown are the means ± SEM. *p < .05. Abbreviations: CyD1, Cyclin D1; IR, irradiation; IRA, irradiation and lithium; b2M, β₂-microglobulin.
inhibition of irradiation-induced microglial activation as shown by COX-2 immunohistological staining, but this did not benefit neurogenesis following irradiation. This result is in accord with our result using an IL6-null mouse-irradiation model, which showed that genetic loss of IL-6 prevented the lithium beneficial effect on cell birth in the DG as shown by BrdU pulse/chase experiment (supplemental online Fig. 3) compared with that seen with wild-type mice. In further support of these observations, there is an increasing body of evidence suggesting that inflammation has beneficial effects on brain recovery in experimental and clinical traumatic brain injury [36], neurodegenerative diseases [37], and ischemia [38]. Thus it has been suggested that activated microglia may help in promoting optimal recovery [39].

Collectively our data show that lithium promotes NSPC proliferation and commitment to the neuronal lineage following irradiation. They also provide proof of principle for the use of lithium in the clinic in the context of promoting postirradiation neurogenesis and tissue repair. Our data also reveal that lithium assists in reducing oligodendrocyte loss induced by brain irradiation, similar to its ability to promote Schwann cell proliferation in the peripheral nervous system [40] and its protective effect in an in vivo model of induced allergic encephalomyelitis [41]. These data imply that lithium promotes normal neuronal function by ensuring proper myelination following irradiation. The question remains whether the use of lithium provides a functional behavioral recovery. Accordingly we have assessed the effect of irradiation using the MWM paradigm. Studies from the literature report either reduced abilities [11, 42, 43] or no difference [44] using this behavioral test. In this work we have found that the apparent latency to find the platform is modestly reduced in irradiated compared with nonirradiated groups in the reversal form of the MWM where the submerged platform location is changed to the quadrant diametrically opposed to that held previously. One explanation we favor is that previous training has influenced the response of the unirradiated mice [45]. The reversal tests are run 24 hours after a probe trial when the platform is removed and the mice have to swim with no escape. Therefore the control group may have learned that the platform is not present and thus offers a reduced stimulation. Indeed, in forced swimming experiments a reduced mobility reflects a relatively successful coping strategy for energy conservation [46]. However, the end point of the experiment was not different between groups in term of time spent in the target quadrant (not shown), platform crossings (not shown), or time spent in the platform area (not shown). Because these differences were subtle and certainly not sufficiently large enough, we did not pursue further investigation of the behavioral effects of lithium treatment following irradiation. Moreover, lithium has previously
been shown to improve cognitive performances of irradiated mice when used as a pretreatment [11]. In our study we used lithium as a postirradiation treatment with the view that it would be more acceptable in a clinical setting. Indeed administering lithium to patients as a pretreatment might be damaging because it is likely to induce NSPC to proliferate prior to radiotherapy. Indeed, quiescent NSPCs are somewhat protected from irradiation, whereas when induced into cycle they are potentially more vulnerable to radiation.

CONCLUSION
We have found here that lithium stimulates NSPC proliferation and differentiation following cranial irradiation while also reducing oligodendrocyte loss in the DG of juvenile mice. Importantly our data have served as a trigger for a phase I clinical trial in lung cancer patients who are receiving whole-brain prophylactic radiotherapy to prevent the occurrence of cranial metastases. We thus believe the beneficial cellular and molecular changes generated using lithium as described here add hope that patients receiving radiotherapy during the course of cancer management might receive improved neurogenic recovery post-treatment.

ACKNOWLEDGMENTS
We thank Dr. A. Peace for performing serum lithium testing in mice. This work was funded in part by the National Health and Medical Research Council of Australia and Cure Cancer Australia. R.G.R., J.M., and M.E. were supported by the National Health and Medical Research Council funding. J.M. was supported in part by Cancer Australia/Cure Cancer Australia, and D.D. was supported by the Cooperative Research Centre for Biomedical Imaging Development.

Figure 7. Effect of lithium and Am80 treatment on neurogenesis following brain-focused irradiation. (A): Immunohistochemistry for DCX, a marker for neuroblasts, was used to assess the effect of drug treatment on neurogenesis. (B): Quantitation showed that DCX 

| Figure 7. Effect of lithium and Am80 treatment on neurogenesis following brain-focused irradiation. (A): Immunohistochemistry for DCX, a marker for neuroblasts, was used to assess the effect of drug treatment on neurogenesis. (B): Quantitation showed that DCX
|**|**|

|**|**|**|**|

A

CONTROL

IR

IR + Li

IR + Am80

IR + Am80 + Li

B

Dcx

**|**|

DCX positive cells/mm³

control

IR

IR+Li

IR+Am80

IR+Am80+Li

|**|**|

p < .05; ***, p < .01; ***, p < .001. Abbreviations: IR, irradiation; Dcx or DCX, doublecortin.

|**|**|

Author Contributions

J.M.: manuscript writing, conception and design, collection and/or assembly of data, data analysis and interpretation, financial support, final approval of manuscript; C.S.M., D.D., E.L., and J.H.: collection and/or assembly of data, data analysis and interpretation; S.L.: collection and/or assembly of data; K.S.: provision of study material and manuscript writing; M.E.: conception and design, provision of study material; D.M.A. and G.W.: manuscript writing, conception and design, final approval of manuscript; J.L.S.: manuscript writing, conception and design, collection and/or assembly of data, data analysis and interpretation, final approval of manuscript; R.G.R.: manuscript writing, conception and design, financial support, final approval of manuscript.

Disclosure of Potential Conflicts of Interest

The authors indicate no potential conflicts of interest.
REFERENCES

1 Hertzberg H, Huk W, Ueberall MA et al. CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings in long-term survivors of childhood ALL—An evaluation of the interferences between morphology and neuropsychological performance. The German Late Effects Working Group. Med Pediatr Oncol 1997;28:387–400.

2 Riva D, Giorgi C. The neurodevelopmental price of survival in children with malignant brain tumours. Childs Nerv Syst 2000;16:751–754.

3 Roman DD, Sperduto PW. Neuropsychological effects of cranial radiation: Current knowledge and future directions. Int J Radiat Oncol Biol Phys 1995;31:983–998.

4 Alvarez-Buylla A, Lim DA. For the long run: Maintaining germineral niches in the adult brain. Neuron 2004;41:683–686.

5 Doetsch F, Garcia-Verdugo JM, Alvarez-Buylla A. Cellular composition and three-di-dimensional organization of the subventricular germinal zone in the adult mammalian brain. Neurosci 1997;17:5046–5061.

6 Eriksson PS, Perilieva E, Bjork-Eriksson T et al. Neurogenesis in the adult human hippocampus. Nat Med 1998;4:1313–1317.

7 Monje ML, Vogel H, Masek M et al. Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol 2007;62:515–520.

8 Monje ML, Palmer T. Radiation injury and neurogenesis. Curr Opin Neuro 2003;16:129–134.

9 Fountoulakis KN, Vieta E, Sanchez-Moreno J et al. Treatment guidelines for bipolar disorder: A critical review. J Affect Disord 2005;86:1–10.

10 Rowe MK, Chuang DM. Lithium neuroprotection: Molecular mechanisms and clinical implications. Expert Rev Mol Med 2004;6:1–18.

11 Yazlovtikaya EM, Edwards E, Thotala D et al. Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation. Cancer Res 2006;66:11179–11186.

12 Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003;302:1760–1765.

13 Sanda T, Kuwano T, Nakao S et al. Anti-myeloma effects of a novel synthetic retinoid Am80 (tamibarotene) through inhibition of angiogenesis. Leukemia 2005;19:901–909.

14 Matsushita H, Hijjoka M, Hisatsune A et al. A retinoid acid receptor agonist Am80 rescues neurons, attenuates inflammatory reactions, and improves behavioral recovery after intracerebral hemorrhage in mice. J Cereb Blood Flow Metab 2011;31:222–234.

15 Fukuda A, Fukuda H, Swandel Palmer J et al. Age-dependent sensitivity of the developing brain to irradiation is correlated with the number and vulnerability of progenitor cells. J Neurochem 2005;92:569–584.

16 Emami B, Lyman J, Brown A et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109–122.

17 Shudo K, Kagechika H, Yamazaki N et al. A synthetic retinoid Am80 (tamibarotene) rescues the memory deficit caused by scopolamine in a passive avoidance paradigm. Biol Pharm Bull 2004;27:1887–1889.

18 Shi Y, Chichung Lie D, Taupin P et al. Expression and function of orphan nuclear receptor TLX in adult neural stem cells. Nature 2004;427:78–83.

19 Vorhees CV, Williams MT. Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat Protoc 2006;1:848–858.

20 Malaterre J, Mantamadiotis T, Dworkin S et al. c-Myb is required for neural progenitor cell proliferation and maintenance of the neural stem cell niche in adult brain. Stem Cells 2008;26:173–181.

21 Kawakara K, Nishi K, Suenobu M et al. Oral administration of synthetic retinoid Am80 (tamibarotene) decreases brain beta-amylloid peptides in APP23 mice. Biol Pharm Bull 2009;32:1307–1309.

22 Hyang SW, Jang JS, Kim TH et al. Ionizing radiation induces astrocyte gliosis through microglia activation. Neurobiol Dis 2006;21:457–467.

23 de Oliveira AC, Candelario-Jallo E, Lang-bein J et al. Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia. J Neuroinflammation 2012;9:2.

24 Couillard-Despres S, Winner B, Schaub- beck S et al. Doublecortin expression levels in microglia. J Neuroinflammation 2012;9:2.

25 De Oliveira AC, Candelario-Jallo E, Lang-bein J et al. Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia. J Neuroinflammation 2012;9:2.

26 Bian Q, Shi T, Chuang DM et al. Lithium reduces ischemia-induced hippocampal CA1 damage and behavioral deficits in gerbils. Brain Res 2007;1184:270–276.

27 Yan XB, Hou HL, Wu LM et al. Lithium regulates hippocampal neurogenesis by ERK pathway and facilitates recovery of spatial learning and memory in rats after transient global cerebral ischemia. Neuropharmacology 2007;53:487–495.

28 Sasaki T, Han F, Shioda N et al. Lithium-induced activation of Akt and CaMKII α contributes to its neuroprotective action in a rat microsphere embolism model. Brain Res 2006;1108:98–106.

29 Engell T, Goni-Oliver P, Gomez de Barreda E et al. Lithium, a potential protective drug in Alzheimer’s disease. Neurodegener Dis 2008;5:247–249.

30 Sarkar S, Krishna G, Imanisro S et al. A rational mechanism for combination treatment of Huntington’s disease using lithium and rapamycin. Hum Mol Genet 2008;17:170–178.

31 Wei H, Qin ZH, Senatorov VV et al. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington’s disease. Neuroscience 2001;106:603–612.

32 Chen G, Rajkowska G, Du F et al.Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000;75:1729–1734.

33 Kim JS, Chang MY, Yu IT et al. Lithium selectively increases neuronal differentiation of hippocampal neural progenitor cells both in vitro and in vivo. J Neurochem 2004;89:324–336.

34 Su H, Chu TH, Wu W. Lithium enhances proliferation and neuronal differentiation of neural progenitor cells in vitro and after transplantation into the adult rat spinal cord. Exp Neurol 2007;206:296–307.

35 Wekler EM, Geschwind DH, Palmer TD. Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Mol Psychiatry 2008;13:285–292.

36 Cederberg D, Siesjo P. What has inflammation to do with traumatic brain injury? Childs Nerv Syst 2010;26:221–226.

37 Amulik S, Puentes F, Baker D et al. Inflammation in neurodegenerative diseases. Immunology 2010;129:154–169.

38 Xia W, Han J, Huang G et al. Inflammation in ischaemic brain injury: Current advances and future perspectives. Clin Exp Pharmacol Physiol 2010;37:253–258.

39 Loane DJ, Byrnes KR. Role of microglia in neurotrauma. Neurotherapeutics 2010;7:366–377.

40 Yoshino JE, DeVries GH. Effect of lithium on Schwann cell proliferation stimulated by axolemma- and myelin-enriched fractions. J Neurochem 1987;48:1270–1277.

41 Levine S, Saltzman A. Inhibition of experimental allergic encephalomyelitis by lithium chloride: Specific effect or nonspecific stress? Immunopharmacology 1991;22:207–213.

42 Fan Y, Liu Z, Weinstein PR et al. Environmental enrichment enhances neurogenesis and improves functional outcome after cranial irradiation. J Neurosci 2007;25:38–46.

43 Rola R, Raber J, Rizk A et al. Radiation-induced impairment of hippocampal neurogenesis is associated with cognitive deficits in young mice. Exp Neurol 2004;188:316–330.

44 Madsen TM, Kristjansen PE, Bolwig TG et al. Arrested neuronal proliferation and impaired hippocampal function following fractionated brain irradiation in the adult rat. Neuroscience 2003;119:635–642.

45 McIlwain KL, Mcerwillie MY, Yuva-Paylor LA et al. The use of behavioral test batteries: Effects of training history. Physiol Behav 2001;73:705–717.

46 West AP. Neurobehavioral studies of forced swimming: The role of learning and memory in the forced swim test. Prog Neuro-psychopharmacol Biol Psychiatry 1990;14:863–877.